Levetiracetam Glenmark (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A, which plays a crucial role in the regulation of neurotransmitter release. This binding modulates calcium‑dependent vesicle exocytosis, leading to decreased release of excitatory neurotransmitters and a reduction in neuronal hyper‑excitability that underlies seizures.

The appropriate dose of Levetiracetam Glenmark is individualized and set by the prescribing healthcare professional. Dosage decisions consider factors such as the patient’s age, weight, renal function, seizure type, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for levetiracetam in pregnancy and lactation are limited. The medication should only be used during pregnancy or while breastfeeding if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will evaluate the risk‑benefit profile for each individual case.

To place an order, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details and any necessary import documentation.

Levetiracetam is distinguished by its unique mechanism of binding to SV2A, which differs from many traditional antiepileptics that target ion channels or G‑protein coupled receptors. It generally has a favorable drug‑interaction profile, minimal protein binding, and does not require routine therapeutic drug monitoring, making it a convenient option for many patients.

Levetiracetam Glenmark should be stored at ambient temperature, below 25 °C. Keep the product in its original container, protect it from moisture, excessive heat and direct sunlight to maintain stability and potency throughout its shelf life.

Levetiracetam Glenmark is administered orally, typically as a tablet or oral solution, according to the prescriber’s instructions. It may be taken with or without food, and the dosage schedule is individualized based on the patient’s clinical response and renal function.

Serious risks, although uncommon, include severe allergic reactions such as anaphylaxis, life‑threatening skin conditions like Stevens‑Johnson syndrome or toxic epidermal necrolysis, and the emergence of suicidal thoughts or behaviors. Patients should seek immediate medical attention if they experience any of these symptoms.

Levetiracetam Glenmark should be avoided in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is also advised for patients with severe renal impairment who may require dose adjustments, and for those with a history of psychiatric disorders where seizure control may affect mood.